EDUCATION
|
Brandeis University, Massachusetts |
B.A. |
1976 |
|
|
College of Physicians and Surgeons of Columbia University, New York, NY |
M.D. |
1980 |
Medicine |
PROFESSIONAL EXPERIENCE
| 1980-1983 |
Pediatric Residency, Bronx Municipal Hospital
Center, Bronx, NY |
| 1983-1984 |
Chief Resident Pediatrics, Bronx-Lebanon
Hospital Center, Bronx, NY |
| 1984-1986 |
Fellow in Training, Division of
Allergy/Immunology, Albert Einstein College of Medicine, Bronx, NY |
| 1986-1994 |
Assistant Professor of Pediatrics, Albert
Einstein College of Medicine, Bronx, NY |
| 1986-1996 |
Attending Pediatrician, Bronx Municipal Hospital
Center, Bronx, NY |
| 1989-1999 |
Director Pediatric HIV Services, Bronx-Lebanon
Hospital Center, Bronx, NY |
| 1994-2000 |
Associate Professor of Pediatrics, Albert
Einstein College of Medicine, Bronx, NY |
| 1999-present |
Director Pediatric HIV, Director Division
Pediatric Allergy/Immunology, Jacobi Medical Center/North, Bronx, NY |
| 2001-present |
Director Adult HIV Services, Jacobi Medical
Center/North, Bronx, NY |
| 2001-present |
Professor of Pediatrics, Albert Einstein College
of Medicine, Bronx, NY |
PUBLICATIONS
Marion RW, Wiznia AA, Hutcheon RG, Rubinstein: Fetal AIDS Syndrome Score:
Correlation between severity of dysmorphism and age at diagnosis of immune
deficiency. Am. J. Dis. Child, 141(7):429-431, 1987.
Marion RW, Wiznia AA, Quazi QH, Shepard: Fetal AIDS Syndrome. Birth Defects
Encyclopedia, 1988.
Diamond GW, Gurdin PG, Wiznia AA, Belman AL, Rubinstein A, Cohen HJ: The effect
of congenital HIV infection on the neurodevelopmental status of boarder babies
in foster care. Developmental Medicine & Child Neurology, 32(11):999-1005, 1990.
Schwartz LJ, St. Louis Y, Wu R, Wiznia AA, Rubinstein A, Saenger P: Endocrine
function in children with Human Immunodeficiency Virus. Am J Dis Child,
145(3):330-333, 1991.
Hand IL, Wiznia AA, Checola RT, Kim MH, Noble LM, Daley TJ, Yoon JJ: Human
Immunodeficiency Virus seropositivity in critically ill neonates in the South
Bronx. Pediatr Infect Dis J, 11(1):39-42, 1992.
Hand IL, Wiznia AA, Porricolo M, Lambert G, Caspe WB: Aerosolized pentamidine
for prophylaxis for pneumocystis carinii pneumonia in HIV-Infected infants.
Pediatr Infect Dis J, 13:100-104, 1994.
Nozyce M, Hoberman M, Arpadi S, Wiznia AA, Lambert G, Dobroszycki J, Chang CJ,
St. Louis Y: A 12 month study of the effects of oral ZDV on neurodevelopmental
functioning in a cohort of vertically infected inner city children. AIDS,
8(5):635-639, 1994.
Wiznia AA, Lambert G, Dobrosyzcki J, Porricolo M, Chelyapov N, Israeli V,
Brunnell P, Conroy J, Liu H.K, Baron M, Gold J: Virologic, immunologic and
clinical evaluation of HIV seroreverting children. Journal of Pediatrics,
125(3):352-355, 1994.
Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomon L: Zidovudine use to
reduce perinatal HIV-1 transmission in an urban medical center. Journal of
American Medical Association, 275(19):1504-06, 1996.
Dobroszycki J, Abadi J, Lambert G, Beenhouwer DO, Truong TH, Wiznia AA:
Testicular abscess due to streptococcus pneumoniae in an infant with Human
Immunodeficiency Virus Infection. Clin Infect Dis, 24:84-5, 1997.
McKinney R, Johnson G, Stanley K, Yong F, Keller A, O'Donnell K, Brouwers P,
Wiznia AA, Mitchell C, McNamara J, Mofenson L,Wells B, Hodge J: A randomized
study of combined zidovudine-lamivudine versus didanosine monotherapy in
symptomatic, therapy-naive, HIV-1 infected children ACTG 300. Journal of
Pediatrics, 133(4):500-8, 1998.
Pavlakis S, Lu D, Frank Y, Wiznia AA, Elderberg D, Barnett T, Hyman R: Brain
lactate and N-acetylaspartate in pediatric AIDS encephalopathy. Annals
Neurology, 19:383-385, 1998.
Krogstad P, Wiznia AA, Luzuriaga K, Danker W, Nielsen K, Kerr B, Hendricks A,
Gersten M, Boczany B, Spector S, Bryson Y: Treatment of Human Immunodeficiency
Virus 1-infected infants and children with the protease inhibitor nelfinavir
mesylate. Clin Infect Dis, 28(5):1109-18, 1999.
McGowan JP, Crain M, Wiznia AA, Blum S: Combination antiretroviral therapy in
Human Immunodeficiency Virus-Infected pregnant women. American Journal of
Obstetrics and Gynecology, 94(5 pt 1):641-6, 1999.
VanDyke R, Korber B, Popek E, Macken C, Widmayer S, Bardeguez A, Hanson C,
Wiznia AA, Luzuriaga K, Viscarello R, Wolinsky S: The Ariel Project: A
prospective cohort study of Maternal-Child Transmission of Human
Immunodeficiency Virus Type 1 in the era of maternal antiretroviral therapy.
Journal of Infectious Diseases, 179(2):319-28, 1999.
Wilson CC, Brown RC, Korber BT, Wilkes BM, Ruhl DJ, Sakamoto D, Kunstman K,
Luzuriaga K, Hanson IC, Widmayer SM, Wiznia AA, Clapp S, Ammann AJ, Koup RA,
Wolinsky SM, Walker BD: Frequent detection of escape from cytotoxic T-Lymphocyte
recognition in Perinatal Human Immunodeficiency Virus (HIV) type 1 transmission:
The Ariel Project for the Prevention of Transmission of HIV from Mother to
Infant. Journal of Virology, 73(5):3975-85, 1999.
Borkowsky W, Stanley K, Douglas SD, Lee S, Wiznia AA, Pelton S, Yogev R,
McIntosh K, Nachman and the Pediatric AIDS Clinical Trials Group 338 Study Team.
Immunologic response to combination nucleoside plus protease inhibitor therapy
in stable antiretroviral-experienced HIV-infected children. Journal of
Infectious Diseases, 182:96-103, 2000.
Nachman S, Stanley K, Yogev R, Pelton S, Wiznia AA, et al.: A Randomized Trial
of One or Two Nucleoside Analog Therapy in Stable Antiretroviral Experienced
HIV-Infected Children (PACTG 338). Journal of American Medical Association,
283(4):492-8, 2000.
Spiegel HML, Chandwani R, Sheehy ME, Dobroszycki J, Fennelly G, Wiznia AA,
Radding J, Rigaud M, Pollack H, Borkowsky W, Rosenberg M, Nixon DF.: The impact
of early initiation of antiretroviral drug treatment on the HIV-1 specific
cytotoxic T cell responses in HIV-1 infected children. J Infect Dis, 182:88-95,
2000.
Wiznia AA, Stanley K, Krogstad P, et al.: Combination nucleoside analogue(s)
reverse transcriptase inhibitors plus nevirapine, nelfinavir or ritonavir in
stable antiretroviral therapy-experienced HIV-infected children. Results of
randomized controlled trial-Pediatric AIDS Clinical Trials Group 377. AIDS
Research and Human Retroviruses 16(12):1113-1121, 2000.
Eshelmann SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S,
Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. Analysis of HIV-1 drug
resistance in children receiving nucleoside analogue reverse-transcriptase
inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical
Trials Group 377). J Infect Dis, 183:1732-38, 2001.
Llonrens XS, Nelson RP, Emmanuel P, Wiznia AA, Mitchell C, Church J, Sleasman J,
Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S, and the CNAA3006
Study Team: A randomized, double-blind study of triple nucleoside therapy of
abacavir, lamivudine and zidovudine versus lamivudine and zidovudine in
previously treated HIV-1 infected Children. Pediatrics, 107(1):e4, 2001.
Krogstad P, Eshleman SH, Geng Y, Jackson J B, Wantman M, Korber B, Lang D,
Wiznia A, Johnson G, Nachman S, Palumbo P. Vertical transmission of Subtypes D
and A/G Human immunodeficiency virus Type 1 in the United States. AIDS Res Hum
Retroviruses (United States), 18(6) p413-7, Apr 2002.
Krogstad P, Lee S, Johnson G, Nachman S, et al and Wiznia AA for the Pediatric
AIDS Clinical Trials Group Study Team. Combination nucleoside analogue(s)
reverse transcriptase inhibitors plus nevirapine, nelfinavir or ritonavir in
stable antiretroviral therapy-experienced HIV-infected children. Week 48
analysis of Pediatric AIDS Clinical Trials Group 377. Clinical Infectious
Diseases, 34:991-1001, 2002.
Nachman S, Lindsey JC, Pelton SI, Mofenson L, McIntosh K, Wiznia A, Stanley K,
Yogev R. Growth in HIV-Infected Children Receiving Ritonavir-Containing
Antiretroviral Therapy. Arch Pediatr Adolesc Med (United States), 156(5)
p497-503, May 2002.
Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EF, Krogstad
PA, Nachman S. Reported Adherence as a Determinant of Response to Highly Active
Antiretroviral Therapy in HIV-Infected Children. Pediatrics (United States),
109(4) pe61, Apr 2002.
Yogev R, Lee S, Wiznia AA, et al. for the Pediatric AIDS Clinical Trials Group
338 Study Team. Stavudine, nevirapine and ritonavir in stable, antiretroviral
therapy experienced HIV-infected children (Pediatric AIDS Treatment Group
Protocol 338, Step 2). Pediatr Infect Dis J (United States), 21(2) p119-25, Feb
2002.
Wiznia AA, Cunningham C. Pediatric Antiretroviral Therapy. Office of the Medical
Director, AIDS Institute, New York State Department of Health.
Guidelines_Update@hivguidelines.org 4/2002.
Okunseri, C., Badner, V., Wiznia, A., Rosenberg, M.: Dental visits by pediatric
HIV-infected medical patients. NY State Dental Journal, in press.
Okunseri, C., Badner, V., Wiznia, A.A., Rosenberg, M.: Prevalence of oral
lesions and CD4+ percent in HIV-infected children on antiretroviral therapy.
AIDS Patient Care and STDs, in press. |
